We examined the effect of la,25-dihydroxyvitamin D3 (la,25(0H)2D3) and a variety of vitamin D analogs on proliferation and differentiation of normal and leukemic myeloid clonogenic cells. Only cells from myeloid leukemic lines that contained relatively mature cells (HL-60, U937, THP, HEL, Ml) were induced to differentiate and were inhibited in their clonal growth by exposure to la,25(0H)hD (50% inhibition, 3 X 10-8-8 X 10-1O M). A fluorinated analog of vitamin D was 5-10-fold more potent than la,25(OH)2D3. Cells from a human myeloblast line (KG-1) and normal human granulocyte-monocyte stem cells (GM-CFC), both of which depend on colony-stimulating factor (CSF) for clonal growth, were stimulated in their clonal proliferation by la,25(OH)2D3 in the presence of suboptimal concentrations of CSF. Leukemic cells from 10 of 14 patients with myeloid leukemia, but not normal GM-CFC from 12 patients in remission, were markedly inhibited in their clonal proliferation by la,25(0H)2D3. Our results suggest that la,25(OH)2D3 may be a cofactor in hematopoiesis and that vitamin D analogs may have a differential effect on normal versus leukemic growth.
Introduction
The active form of vitamin D is la,25-dihydroxyvitamin D3 (la,25(OH)2D3),' which results from sequential hydroxylation in the liver and kidney ofthe parental vitamin D3. la,25(0H)2D3 is generally accepted as the principal form of vitamin D responsible for calcium homeostasis (1) . The classic target organs of this secosteroid are the intestine, bone, and kidney. Recently, the vitamin D endocrine system was found to interact with the hematopoietic system. The evidence for these interactions is that:
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1. Abbreviations used in this paper: I a,25(OH)2D3, Ia,25-dihydroxyvitamin D3; AML, acute myelogenous leukemia; CFU-GM, colonyforming unit-granulocyte-macrophage; CML, chronic myelogenous leukemia; CSF, colony-stimulating factor; 24,24-F2-la,25(OH)2D3, 24,24-difluoro-I a,25-dihydroxyvitamin D3; FCS, fetal calf serum; GM-CFC, granulocyte-macrophage colony-forming cell; NBT, nitroblue tetrazolium.
(a) hematopoietic cells have receptors for lIa,25(OH)2D3 (2, 3); (b) I a,25(OH)2D3 modulates myeloid stem cell colony-forming unit-granulocyte-macrophage (CFU-GM) differentiation towards macrophages (4, 5) ; (c) very low concentrations of lIa,25(OH)2D3 (10-10 M) induce neoplastic cells from several myeloid cell lines (HL-60, U937) to differentiate to macrophagelike cells (6) (7) (8) (9) ; and (d) activated, normal macrophages can synthesize lIa,25(OH)2D3 (10) .
Acute myelogenous leukemia (AML) arises from neoplastic transformation ofa myeloid stem cell. Most acute myelogenous leukemia cells are unable to undergo terminal differentiation. Instead, these cells remain in the proliferative pool and rapidly accumulate. In the present study, we investigated the effects of I a,25(OH)2D3 and a variety of other vitamin D analogs on the clonal proliferation of both myeloid leukemia cell lines blocked at different stages of maturation and leukemic myeloid stem cells harvested from patients. The results were contrasted with the effects of the same vitamin D compounds on proliferation of normal myeloid progenitors harvested from leukemic patients in remission. Further studies were performed to attempt to elucidate the mechanism by which vitamin D compounds affect hematopoietic proliferation.
Methods
Cells. Several myeloid cell lines were used in this study; details and references are given in Table I . These cell lines were cultured in tissue culture flasks (Miles Laboratories, Naperville, IL) in alpha medium (Flow Laboratories, Inc., McLean, VA) with 10% fetal calf serum (FCS; Irvine Scientific, Santa Ana, CA). For plating experiments, only cells in logarithmic growth were used. The calcium concentration in the media was 1.8 mM.
Bone marrow was obtained from healthy volunteers and leukemic patients by aspiration from the iliac crest after written consent was obtained. For anticoagulation, preservative-free heparin prepared from porcine intestinal mucosa (5 U/ml; O'Neal, Jones & Feldman, St. Louis, MO) was used. The mononuclear cells were isolated by centrifugation on Ficoll-Hypaque gradients, washed twice in phosphate-buffered saline (PBS), and suspended in alpha medium containing 10% FCS and 1% penicillin and streptomycin (Irvine Scientific). Peripheral blood mononuclear cells were obtained with similar techniques from consenting leukemia patients who had a high concentration of leukemia cells in their blood (>30,000 per microliter). Details about the leukemia patients are given in Table III . The bone marrow samples usually contained >95% leukemic cells by morphology. In the samples from the peripheral blood, >80% of the mononuclear cells were neoplastic. The bone marrows from 12 leukemia patients in remission were also studied. Remissions were determined independently by a pathologist and one author (Dr. Munker) using morphology and karyotype analysis. The Colonyformation in soft agar and differentiation studies. Cells were plated in Lux culture dishes in a two-layer soft agar system according to previously described methods (20, 21) . The underlayer contained 0.5% agar; the upper layer, 0.3% agar (Difco Laboratories, Inc., Detroit, MI). The culture medium was alpha medium; in some experiments, Iscove's medium was substituted for alpha medium with similar results. For each plating experiment, 2X stock solutions of agar were prepared by autoclaving with distilled water and the agar was kept at 430C. For each layer, these stock solutions were mixed with prewarmed alpha medium (which contained a final concentration of 17% FCS and 1% penicillinstreptomycin) and 1 ml was carefully pipetted into each culture dish. This mixture became semisolid at room temperature within 20 min. The colony-stimulating factor (CSF) and the compounds to be tested were mixed into the underlayer before solidification of the agar. As a source of CSF, different concentrations of conditioned medium from a human T lymphocyte line (Mo) were used (22). For human bone marrow, 2 X 101 cells were plated. Myeloid cell lines were plated at 1,000-5,000 cells/plate. The plating efficiency varied between 5% (KG) and 38% (K562). The KG cell line (passages [12] [13] [14] [15] [16] [17] [18] [19] [20] formed colonies only in the presence of CSF. FCS was present in all liquid and soft agar cultures.
Cultures were placed in a humidified atmosphere, 5% C02, at 370C. Colonies (.40 cells) were scored after 10-12 d with an inverted microscope. All experiments were done using triplicate or quadruplicate plates per experimental point. Control plates with no CSF were performed for each experiment.
The production of colony-stimulating activity under the influence of I a,25(OH)2D3 was tested by culturing various cell lines (HL-60, HEL, KG-I, THP-1, U937) with 5 X l0-7 M la,25(OH)2D3. After 5 d, the supernatants were harvested and stored at 40C until used. When tested, the supernatants (0.1-10%) were mixed into the lower agar layer and assayed for stimulation ofgranulocyte-macrophage colony-forming cell (GM-CFC).
The induction of differentiation was measured by morphology, histochemistry, and function, including adherence to plastic and reduction of nitroblue tetrazolium (NBT). The NBT reduction was studied as previously described (23) . Briefly, the cells were mixed with an equal volume of a solution containing 1.25 mg/ml NBT (Sigma Chemical Co., St.
Louis, MO), 17 mg/ml bovine serum albumin, and 1 gg/ml 12-O-tetradecanoylphorbol 13-acetate (Miles Laboratories) for 30 min. at 370C, 5% CO2. They were then washed in PBS, cytocentrifuged, fixed in methanol, and stained with Giemsa. For statistical comparisons between different points, Student's t test was used.
Results
Effect of vitamin D metabolites on proliferation and differentiation of myeloid leukemia cell lines. We examined the effect of la,25(OH)2D3 and 24,24-F2-la,25(OH)2D3 on the clonal proliferation ofmyeloid leukemia cell lines blocked at different stages of differentiation ( Fig. 1 , Table I ). (Table II) . In four of the five sensitive lines, the fluorinated vitamin D compound was about 10-50-fold more potent than la,25(0H)2D3 in the inhibition of clonal proliferation (Table  I) . 50% inhibition of colony formation occurred in the concentration range of 3 X 10-9-4 X 10' M 24,24-F2-Ia,25(OH)2D3
for these four myeloid cell lines. Cell lines that could not be induced to differentiate with Ia,25(OH)2D3 also could not be induced to differentiate with the fluorinated compound (Table  II) . The concentration that resulted in 50% of the maximum NBT reduction was 4 X 10-9 M when the HL-60 cells were cultured with la,25(OH)2D3 and 2 X 10-9 M when the cells were cultured with the fluorinated analog (data not shown). We examined the effect of six other vitamin D compounds on the clonal proliferation ofthe HL-60 promyelocytes (Fig. 2) . The inhibition ofcolony formation paralleled the known ability of the analog to bind to the cellular 1,25(OH)2D3 receptor (6) . The rank order of potency of the active compounds was: 24,24-F2-1 a,25(OH)2D3 > 1 a,25(OH)2D3 > 1 a,24R,25(OH)3D3 = 1a,24S,25(OH)3D3. In contrast, Ia-OH-D3, 25-OH-D3, 24S,25(OH)2D3, and 24R,25(OH)2D3 had no effect on clonal growth in the concentrations that we tested (Fig. 2) .
We performed time-response experiments in order to determine the rapidity by which lIa,25(OH)2D3 inhibited the clonal growth of HL-60 cells. The cells were exposed to Ia,25(OH)2D3 M) for various periods of time, washed thoroughly three times, plated in soft agar, and colony formation was determined after 10 d of culture. Colony formation was inhibited by 50% within 20 h of exposure to la,25(OH)2D3 and was totally inhibited by 48 h (Fig. 3) . Paradoxically, we noted a consistent, significant stimulation of colony formation if the cells were exposed to lca,25(OH)2D3 for a short time (1-10 h) (P1 . 0.05). The stimulation was in the range of 50%. A similar enhancement of clonal growth was noted when HL-60 promyelocytes were exposed to 24,24-F2-1a,25(OH)2D3 and when U937 monoblasts were briefly (8 h) exposed to Ia,25(OH)2D3 (10-6 M) (data not shown).
We have developed a unique human myeloblast cell line, KG-1, whose clonal proliferation in soft agar culture is dependent on CSF. We examined in detail the effect of Ia,25(OH)2D3 on the clonal growth of the KG-l cells (Fig. 4) 12 myeloid leukemia patients who were in remission postchemotherapy (Fig. 5 B) . The GM-CFC from leu- Fig. 5 A) ; also, marrow cells were harvested from 12 AML patients in remission (Fig. 5 B) . The (Fig. 6) . However, in the presence of 15% maximally stimulating concentrations of CSF, the ad- 
Discussion
Using eight myeloid cell lines, we have found that the cell lines that were induced to differentiate by la,25(OH)2D3 were always inhibited in their clonal growth by la,25(OH)2D3. The responsive cells were relatively more mature (HL-60, promyelocytes; U937 and THP-1, monoblasts; HEL, bipotent erythroblastsmonoblasts; Ml, late myeloblasts) than the unresponsive cells We and others have found that the inhibition ofclonal growth and induction of differentiation of HL-60 by various vitamin D compounds parallels their known ability to bind to cellular la,25(OH)2D3 receptors (6, 8) . We (8) . Likewise, clones of HL-60 with decreased receptor protein (HL-60 blast) can neither be induced to differentiate into macrophages nor inhibited in their clonal growth by la,25(0H)2D3 (8, 28) . Taken together with other studies (6) , the data are consistent with 1 a,25(OH)2D3 inhibiting clonal proliferation and inducing differentiation of HL-60 through cellular la,25(OH)22D3 receptors. However, as held by Olsson et al. (7) , presence ofthese cellular receptors does not assure that the myeloid leukemia cells can be induced to differentiate by vitamin D compounds.
Time-response experiments showed that HL-60 cells required -20 h exposure to la,25(OH)2D3 (5 X l0-7 M) to produce a 50% clonal inhibition of growth. Another study has found that the transcription ofthe c-myc oncogene, which is associated with cell division, begins to decrease within 4 h of exposure of HL-60 to 10-8 M la,25(OH)2D3 (29). We and others previously showed that HL-60 cells must be exposed to 1 a,25(OH)2D3 for at least 18-24 h to induce substantial differentiation (8, 26) . These experiments suggest that the ability of la,25(OH)2D3 to inhibit clonal growth of leukemia cells is temporally associated with the ability of la,25(OH)2D3 to induce differentiation ofthe cells (8) .
Paradoxically, we found that brief exposure (<10 h) to 10-6 M la,25(OH)2D3 significantly enhanced clonal growth of the HL-60 cells. We do not as yet understand why this occurs. We showed that HL-60 does not synthesize detectable CSF after brief exposure to 1 a,25(OH)2D3. We are now examining alteration in CSF receptor number or affinity in these cells after brief exposure to la,25(OH)2D3.
We found that clonal growth ofthe leukemic cells from about 70% of the AML and CML patients that we examined was inhibited by either 1a,25(OH)2D3 or 24,24-F2-I a,25(OH)2D3 in vitro. In most cases, the clonal growth was markedly inhibited at rather low concentrations ofthe vitamin D compounds (range, 5 X 10-7-3 X 10-" M). An exception was patient No. 3, whose leukemic cells increased their clonal growth about fourfold in the presence of either 5 X 10-8 M la,25(OH)2D3 or 24,24-F2-la,25(0H)2D3. The neoplastic cells ofthis patient were relatively immature (Ml, FAB classification) and had an unusual chromosomal abnormality. Further patients with similar neoplastic cells must be studied to know if such a stimulation also occurs in other cases.
In contrast to leukemia cells from the majority of patients, normal bone marrow myeloid progenitors (CFU-GM) harvested from 12 leukemic patients in remission were not inhibited in their clonal growth when cultured with either la,25(OH)2D3 or 24,24-F2-la,25(OH)2D3. Why these vitamin D compounds preferentially inhibited in vitro the proliferation of leukemic, but not normal, human myeloid stem cells is not clear. Differences in receptor number or affinity, or the activation ofdifferent genes and metabolic pathways may account for this differential effect. Since 1 a,25(0H)2D3 causes alterations in Ca transport in several types ofcells, one might speculate that leukemic colonyforming cells are particularly sensitive to these alterations.
We have previously studied normal and malignant myeloid colony formation in the presence of all-trans-retinoic acid (21) . Retinoic acid also suppresses the clonal growth of neoplastic cells from most myeloid leukemia lines and patients, but stimulates normal CFU-GM by >100%. Evidence suggests that retinoic acid acts upon normal and malignant hematopoietic progenitor cells through a mechanism different from that of la,25(OH)2D3 (8, 20) .
Our study suggests that lIa,25(OH)2D3 can act as a hematopoietic cofactor that promotes clonal growth of myeloid stem cells. We found that in the presence of submaximal concentrations of CSF, la,25(OH)2D3 stimulated the clonal growth of normal human bone marrow GM-CFC. A similar result was obtained with the KG-l cell line, which is dependent on CSF for its clonal growth. This cell line was also stimulated to form colonies when only la,25(OH)2D3 was added to the cultures. 1ca,25(OH)2D3 did not stimulate the marrow or KG-l cells to produce detectable CSF. The increased clonal growth in the presence of la,25(0H)2D3 and submaximal concentrations of CSF may reflect an increased responsiveness to CSF due to effects on the number and/or affinity of CSF receptors on the target cells. la,25(OH)2D3 may be stimulating KG-l clonal growth in cultures in the absence of exogenous CSF by making the cells more responsive to endogenous CSF present in FCS. Work is in progress in our laboratory to examine these hypotheses.
Vitamin D analogs might eventually be useful in treating patients with myeloid leukemias, either alone or in combination with other agents. Other studies showed that administration of lIa,25(OH)2D3 significantly prolonged the life of mice injected with the Ml transplantable leukemia cells (30) . Our present study found, however, that the 50% effective concentration of la,25(OH)2D3 that is required both for clonal inhibition and differentiation of human leukemic cells in vitro is 10-100-fold higher than the serum level of la,25(OH)2D3 present in vivo (31) . In addition, a smaller percentage of la,25(0H)2D3 is bound to binding proteins in our culture conditions than is bound in normal human plasma, which might preferentially increase the in vitro as compared with the in vivo potency of I a,25(OH)2D3. We have treated a series of patients with the myelodyplastic syndrome with oral Ia,25(OH)2D3 with no apparent success; however, theoretically desirable levels of 1 a,25(OH)2D3 could not be achieved without the patients developing hypercalcemia (32) . Several new vitamin D analogs, including I a,25S,26-trihydroxyA&22 vitamin D3, have been developed that induced differentiation of HL-60 cells but that have less ability than la,25(OH)2D3 to cause hypercalcemia (33). Future trials with these new vitamin D analogs may have therapeutic potential.
